Who sells Geron (Gern) stock?
GERN stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, BlackRock Inc., Vanguard Group Inc., Morgan Stanley, Morgan Stanley, Millennium Management LLC, Rafferty Asset Management LLC, and Citigroup Inc.. View insider buying and selling activity for Geron or view top insider-selling stocks.
How has coronavirus affected Geron's stock?
Geron's stock was trading at $1.03 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, GERN shares have increased by 39.8% and is now trading at $1.44. View which stocks have been most impacted by COVID-19.
How much money does Geron (EGR) make a year?
Geron has a market capitalization of $461.66 million and generates $250,000.00 in revenue each year. The biopharmaceutical company earns $-75,620,000.00 in net income (profit) each year or ($0.28) on an earnings per share basis.
Will Geron get delisted or reverse split?
Geron went down to 70-cents a year-and-a-half ago and did not get either delisted or undergo a reverse stock split. A stock needs to remain below $1.00 for 30 consecutive days before delisting is even considered, and even then it's not an immediate consequence; moreover, even in the highly unlikely event Geron does a reverse split, so what?
See more
Will Geron stock go up?
The 5 analysts offering 12-month price forecasts for Geron Corp have a median target of 4.00, with a high estimate of 7.00 and a low estimate of 2.00. The median estimate represents a +210.08% increase from the last price of 1.29.
Is Geron a good stock to buy?
Geron has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
What does Geron company do?
Geron Corporation is a biotechnology company located in Foster City, California, which specializes in developing and commercializing therapeutic products for cancer that inhibit telomerase.
Who owns Geron?
Geron is not owned by hedge funds. The company's largest shareholder is RA Capital Management, L.P., with ownership of 9.4%. For context, the second largest shareholder holds about 7.9% of the shares outstanding, followed by an ownership of 4.8% by the third-largest shareholder.
Will GERN stock recover?
The Wall Street analyst predicted that GERON's share price could reach $4.00 by Nov 2, 2022. The average GERON stock price prediction forecasts a potential upside of 225.2% from the current GERN share price of $1.23.
What is a Geron?
Geron, an elder (from the Greek "γέρων") of an Orthodox monastery (starets in Russian)
Is imetelstat FDA approved?
The FDA has granted a fast track designation to imetelstat for the treatment of adult patients with relapsed or refractory myelofibrosis (MF) who have intermediate-2 or high-risk disease.
What does Geron mean?
Guards; guardianFrench Baby Names Meaning: In French Baby Names the meaning of the name Geron is: Guards; guardian.
"Should I invest in Geron stock?" "Should I trade "GERN" stock today?"
According to our live Forecast System, Geron Corp. stock is a bad long-term (1-year) investment *.
What is the Geron stock price / share price today?
The Geron stock price is 1.460 USD today.
Will GERN stock price drop / fall?
Yes. The Geron stock price may drop from 1.460 USD to 1.139 USD...
Will GERN stock price grow / rise / go up?
No. See above .
Will GERN stock price crash?
According to our analysis, this can happen.
Will Geron stock price hit 10 USD price in a year?
Not within a year. See above .
Will Geron stock price hit 20 USD price in a year?
Not within a year. See above .
Will Geron stock price hit 50 USD price in a year?
Not within a year. See above .
Is Geron a phase 2 company?
Is Geron stock up?
FOSTER CITY, Calif., Jun 17, 2021--Geron Corporation (Nasdaq: GERN), a late-s tage clinical biopharmaceutical company, today announced the publication of data from the IMbark Phase 2 clinical trial in the Journal of Clinical Oncology in a paper entitled, "Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis." The publication highlights the clinical benefits observed in the study, including symptom response and overall survival, as
